Searched for
SUN PHARMA SPECIALTY BUSINESS
Why the matinee remains cinema's quiet pleasureEscaping the midday heat for the cool, dark sanctuary of a cinema offers a unique rebellion. Inside, the world outside fades as the screen ...- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- Capricorn ♑ July 2026 Horoscope, Monthly Predictions: Delays Could Lead to Bigger Rewards Than Expected♑ Capricorn Monthly Horoscope (1st July 2026 to 31st July 2026): The Capricorn Monthly Horoscope indicates a month focused on work and pers...
- India's GIC Re plans to reduce share of overseas property risk as climate losses riseIndian reinsurer GIC Re is strategically shifting its overseas business focus. Amidst escalating climate-related losses globally, the compa...
- Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Central Drugs Laboratories find 46 drug samples not of standard quality for MayHealth officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratorie...
- Sensex rises 291 points, Nifty closes above 24,100; Tech Mahindra, Sun Pharma among top gainersIndian stock markets saw a positive start on Monday, with Sensex and Nifty inching up after Friday's dip. Tech Mahindra led the gains, whil...
- Reliance, financials and defence top investment picks as market leadership broadens: Rahul ShahReliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...
- Carlyle eyes $1 billion raise via auto, healthcare IPOsPrivate equity giant Carlyle is gearing up for significant IPOs in India, planning a $500 million listing for its automotive platform, High...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- For long-term investors: Boring portfolio that wins difficult years; 5 large-cap stocks with upside potential up to 20%A sector leader is not just the company with the largest market share. Market share matters, but it is a result, not a cause. The cause is ...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- Reliance to turn crude into carbon fibre, green chemicals, other materials in major O2C overhaulReliance Industries is set to reinvent its oil-to-chemicals business. The company will convert crude oil into advanced materials and green ...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Novyte, Chemvera partner to create pathway for AI-driven material discoveryThis collaboration leverages Novyte's AI engine for materials discovery and Chemvera's manufacturing expertise, creating an end-to-end Indi...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
Load More
